Creatine Monohydrate for Stage IV Cancer

Also known as: Creatine

Creatine may enhance anti-tumor immune cell energy metabolism and reduce cancer-related fatigue.

Mechanism of Action

Creatine supports ATP production in tumor-infiltrating T cells and NK cells, enhancing their anti-tumor cytotoxicity. It also reduces cancer-related fatigue and preserves muscle mass during chemotherapy-induced cachexia.

General mechanism: Phosphocreatine energy buffer. ATP stabilization, mitochondrial protection, anti-apoptotic, muscle preservation.

Current Evidence

Preclinical studies show creatine-fed T cells have enhanced anti-tumor activity. Clinical trials for cancer-related fatigue show benefit. Immune-enhancing effects are an emerging area.

Clinical Status: Phase II for cancer fatigue. Immune enhancement studies preclinical.

Safety Profile

Extremely safe. Decades of safety data. GI effects at high loading doses. Water retention. Safe long-term at 3-5g/day.

Key Research Questions

View glossary entry →

← Back to Stage IV Cancer Research